46-60 of 937
Disease-Modifying Advances in ATTR-CM Management
Heart MattersDisease-Modifying Advances in ATTR-CM Management
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstractsIntegrating CMR and Genetics to Improve ATTR-CM Diagnosis
Ryan Quigley
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Heart MattersHidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Heart MattersPlasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
FAI and the Future of Cardiac Risk Stratification
Heart MattersFAI and the Future of Cardiac Risk Stratification
Redefining ATTR-CM Care in the Age of Targeted Therapy
On the Frontlines of ATTR-CMRedefining ATTR-CM Care in the Age of Targeted Therapy
Steve Jackson, PharmD
David Rind, MD, MSc
- advertisement
Tracking Disease Progression in ATTR-CM
On the Frontlines of ATTR-CMTracking Disease Progression in ATTR-CM
Ryan Quigley
Joban Vaishnav, MD
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
On the Frontlines of ATTR-CMUnderstanding Vutrisiran’s Cardiac Effects in HELIOS-B
Steve Jackson, PharmD
Karola Jering, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CMRNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD
Chadi Alraies, MD, MPH, FACC
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CMCan AI Transform How We Diagnose ATTR-CM?
Ryan Quigley
Frederick Ruberg, MD
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology AcademyOCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Mike Sharma, MD, MSc, FRCPC
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology AcademyBeyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Ashkan Shoamanesh, MD
- advertisement
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CMATTRibute-CM Findings on Acoramidis and Cumulative CV Events
Ryan Quigley
Ahmad Masri, MD, MS
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart MattersRedefining ATTR Treatment: Key Mechanisms and Emerging Data
Ahmad Masri, MD, MS
When Alopecia Areata Signals More than Hair Loss
DermConsultWhen Alopecia Areata Signals More than Hair Loss
